PUMA
24.3.2024 09:01:26 CET | Business Wire | Press release
Globally renowned sports brand, PUMA, proudly unveiled the highly anticipated Jamaican Olympic Association kits during an unmissable showcase of speed at the ISSA Boys & Girls Championships in Kingston, Jamaica.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240324802511/en/
Sports company PUMA unveiled the Jamaican Olympic Association kits at the ISSA Boys & Girls Championships in Kingston, Jamaica. (Pictured: Shanieka Ricketts) (Photo: Business Wire)
The reveal, at the Jamaica National Stadium, came in front of more than 25,000 track enthusiasts from across the country, all gathering to feast their eyes on the future of Jamaican track & field. It served as the perfect platform to showcase the cutting-edge apparel that will adorn the fastest athletes on the planet this summer in Paris – many of whom competed at this event in their teenage years.
Jamaica’s most prestigious athletes took centre stage for the grand reveal, including the likes of double, double Olympic Champion, Elaine Thompson-Herah; the fastest woman alive at the 200 meters, Shericka Jackson; reigning Olympic Champion at the 110m hurdles Hansle Parchment; the second fastest man of all-time, Yohan Blake; former 100m World Record holder, Asafa Powell; World U-20 Triple Jump Champion Jaydon Hibbert; Rushell Clayton, Ackeem Blake and many more. They were joined side-by-side on the track by young athletes from PUMA sponsored high schools.
The ISSA Boys & Girls Championships, often referred to as "Champs," has gained immense popularity and recognition for its ability to showcase young Jamaican talent who have gone on to achieve greatness on both the domestic and international stage. The Championships not only celebrate sporting excellence but also serve as a symbol of unity, passion and pride for the Jamaican community.
"Champs is the beating heart of Jamaica. For decades, it has produced an unimaginable number of Olympians, World Champions and World Record holders, who themselves have created some of the most memorable moments in sports history. Tonight, here in Kingston, we created another,” said PUMA's Chief Executive Officer, Arne Freundt.
The new designs represent a perfect harmony of speed and fashion, reflective of the symbiotic relationship between these two giants of track & field.
Rooted in elite performance, they have been designed to evoke speed with cut lines strategically placed to accentuate the physique of the athletes whilst also providing a showstopping visual via Warpspeed graphics that emphasise the beauty of an athlete in motion. Engineered jacquard fabric is ergonomically shaped to contour the back muscles for heat reduction and breathability, with thermoadapt technology regulating body temperature to enable optimum performance.
“In their truest form these kits are an expression of speed. Speed has always been PUMA’s vantage point. It is what enables us to see the game differently, challenge convention and create moments that will live with us forever. We can’t wait to experience more in Paris this summer,” added Arne.
Maria Valdes, Chief Product Officer at PUMA, commented: “What makes these kits special is how closely they have been created in collaboration with our athletes. They are more than just a kit – they are a statement of the collective ambition shared between PUMA and Jamaica. They are a symbol of pride for the PUMA family, and we hope that they become a symbol of pride for Jamaicans this summer and long into the future.”
To find out more about PUMA follow @pumarunning on Instagram.
PUMA
PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 21,000 people worldwide, and is headquartered in Herzogenaurach/Germany.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240324802511/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
